EQS-News: PL BioScience Announces Conferences Attendance

PL BioScience Announces Conferences Attendance

Aachen, Germany, September 30, 2025 – PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced its participation in six life sciences conferences this fall.

Meet our management team and marketing colleagues at one of the upcoming conferences:

Festival of Biologics September 30 – October 2 in Basel, Switzerland Anna Kolkmann (Sales Manager) and Maria Noronha (Marketing Specialist) will be present Booth: 501C Scheduling meetings is possible through the Terrapinn Event App

BioJapan October 8 – 10 in Yokohama, Japan Jungsoo Park (VP Marketing & Sales) and Kana Miyakubi (Sales Account Manager) will be present Booth: B-68 at the EU-Japan Centre for Industrial Cooperation Pavilion

Innovative Therapies Days 2025 October 9 – 10 in Besançon, France Silver Sponsor of the conference Cécilia Mesa (Sales Manager) will be present and exhibit a poster Booth: 6 Scheduling meetings is possible through the B2Match platform

CPHI Frankfurt 2025 October 28 – 30 in Frankfurt, Germany Hatim Hemeda (CEO & Co-Founder), Christian Wilkes (CFO & Co-Founder) and Jungsoo Park will be present Booth: 4S115 Scheduling meetings and contacting are possible through the CPHI Event Planner App

BIO-EUROPE 2025 November 3 – 5 in Vienna, Austria Hatim Hemeda and Christian Wilkes will be present Scheduling meetings through the partneringONE system

Cell 2025 November 11 – 12 in London, United Kingdom Network & Programme Sponsors Silke Isenhardt (Field Application Scientist) and Maria Noronha (Marketing Specialist) will be present and exhibit a poster Booth: 54 Contact will be possible through the event app from November

About PL BioScience:

PL BioScience GmbH, a life science company located in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (HPL). The company has pioneered proprietary technology to produce fully artificial HPL, allowing for a fully lab-made, scalable supply of HPL. PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products tailored for a range of applications – the ELAREM^TM platform. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. PL BioScience is the only company worldwide holding a patent for the gamma-irradiation of HPL, covering the manufacturing process for ELAREM™ Ultimate-FD PLUS.

For more information on PL BioScience and the ELAREM™ platform, visit: https://www.pl-bioscience.com/

Contact: Dr. Hatim Hemeda, CEO PL BioScience GmbH +49(0)24195719-100 info@pl-bioscience.com

Media contact: MC Services AG Raimund Gabriel, Dr. Regina Lutz +49 (0)89 210 228 0

U.S.: Catherine Featherston +1-203-444-4393 E-Mail: plbioscience@mc-services.eu